(Q34007485)

English

Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels?

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

30 July 2017

Are neuropsychological impairments in children with early-treated phenylketonuria (PKU) related to white matter abnormalities or elevated phenylalanine levels? (English)

1 reference

Europe PubMed Central

30 July 2017

neuropsychology

1 reference

based on heuristic

inferred from title

phenylketonuria

1 reference

based on heuristic

inferred from title

5

object named as

Vicki Anderson

1 reference

Europe PubMed Central

30 July 2017

author name string

Peter J Anderson

1

1 reference

Europe PubMed Central

30 July 2017

Stephen J Wood

2

1 reference

Europe PubMed Central

30 July 2017

Dorothy E Francis

3

1 reference

Europe PubMed Central

30 July 2017

Lee Coleman

4

1 reference

Europe PubMed Central

30 July 2017

Avihu Boneh

6

1 reference

Europe PubMed Central

30 July 2017

publication date

1 January 2007

1 reference

Europe PubMed Central

30 July 2017

Developmental Neuropsychology

1 reference

Europe PubMed Central

30 July 2017

32

1 reference

Europe PubMed Central

30 July 2017

2

1 reference

Europe PubMed Central

30 July 2017

645-668

1 reference

Europe PubMed Central

30 July 2017

Developmental timing of exposure to elevated levels of phenylalanine is associated with ADHD symptom expression

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Interhemispheric interaction during childhood: II. Children with early-treated phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

White matter abnormalities in patients with treated hyperphenylalaninaemia: magnetic resonance relaxometry and proton spectroscopy findings.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Cognitive Deficit Caused by Regional Depletion of Dopamine in Prefrontal Cortex of Rhesus Monkey

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Neuropsychological outcome of subjects participating in the PKU adult collaborative study: a preliminary review

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Executive functioning, memory, and learning in phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of mesocortical dopamine neurons

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Assessment of adult phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Magnetic resonance imaging of the brain in phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Lateralized deficits in visual attention in males with developmental dopamine depletion

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Prefrontal cortex cognitive deficits in children treated early and continuously for PKU.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Phenylketonuria: no specific frontal lobe-dependent neuropsychological deficits of early-treated patients in comparison with diabetics

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Interhemispheric transfer in children with early-treated phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Turnover of the fast components of myelin and myelin proteins in experimental hyperphenylalaninaemia. Relevance to termination of dietary treatment in human phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Inhibition of prepotent responding and attentional flexibility in treated phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Sustained attention and inhibition of cognitive interference in treated phenylketonuria: associations with concurrent and lifetime phenylalanine concentrations

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Motor function under lower and higher controlled processing demands in early and continuously treated phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

The neuropathology of phenylketonuria: human and animal studies

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Tyrosine supplementation in phenylketonuria: diurnal blood tyrosine levels and presumptive brain influx of tyrosine and other large neutral amino acids

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Blood-brain phenylalanine relationships in persons with phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Clinical significance of brain phenylalanine concentration assessed by in vivo proton magnetic resonance spectroscopy in phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Executive function impairment in early-treated PKU subjects with normal mental development.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Associations between phenylalanine-to-tyrosine ratios and performance on tests of neuropsychological function in adolescents treated early and continuously for phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

The effects of high phenylalanine concentrations on serotinin and catecholamine metabolism in the human brain

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Brain phenylalanine concentration in the management of adults with phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Memory and Working-with-Memory: A Component Process Model Based on Modules and Central Systems

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Neurological aspects of adult phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Neurological outcome in adult patients with early-treated phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Psychiatric disorders in adult patients with early-treated phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Phenylketonuria: findings at MR imaging and localized in vivo H-1 MR spectroscopy of the brain in patients with early treatment.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Early-treated phenylketonuria: adult neuropsychologic outcome.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Chemical neuromodulation of frontal-executive functions in humans and other animals.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

D1 Dopamine Receptors in Prefrontal Cortex: Involvement in Working Memory

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Effects of concurrent phenylalanine levels on sustained attention and calculation speed in patients treated early for phenylketonuria.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Randomised controlled trial of tyrosine supplementation on neuropsychological performance in phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Mesoprefrontal dopaminergic neurons: can tyrosine availability influence their functions?

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Brain MRI changes in phenylketonuria. Associations with dietary status.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Regression of neuropsychological deficits in early-treated phenylketonurics during adolescence.

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Deficits in selective and sustained attention processes in early treated children with phenylketonuria--result of impaired frontal lobe functions?

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Individual blood-brain barrier phenylalanine transport determines clinical outcome in phenylketonuria

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Neuropsychology of early-treated phenylketonuria: specific executive function deficits

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

The tower of London test: Validation and standardization for pediatric populatons

1 reference

https://api.crossref.org/works/10.1080%2F87565640701375963

21 January 2018

Identifiers

10.1080/87565640701375963

1 reference

Europe PubMed Central

30 July 2017

1 reference

Europe PubMed Central

30 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34007485&oldid=2022643502"